• Hepatic sEH–Nrf2 Axis in Osteoporosis

  2026-09-07

  The reference study identifies a liver–bone axis in which hepatic soluble epoxide hydrolase reduces circulating 14,15-EET, suppresses Nrf2-ARE antioxidant signaling, and promotes osteoclast differentiation. By combining patient samples, an ovariectomy-induced mouse model, liver-specific sEH knockdown, pharmacological inhibition, and transcriptomics, the work provides a mechanistic framework for studying redox imbalance in osteoporosis.

• LRPPRC–Dasatinib Dual OXPHOS Disruption

  2026-09-07

  The 2026 reference study identifies dasatinib as a synergistic partner for LRPPRC inhibition and shows that the combination suppresses oxidative phosphorylation through complementary effects on mitochondrial- and nuclear-encoded OXPHOS programs. Its screening and mechanistic framework supports biomarker-guided investigation of dual-genome metabolic targeting, while remaining limited to predominantly preclinical cell-model evidence.

• Cy3-UTP for Dynamic RNA Labeling and Kinetics

  2026-09-05

  Cy3-UTP enables covalent fluorescent labeling during transcription, connecting routine RNA production with imaging, interaction assays, and real-time conformational analysis. Its strongest use case is a controlled fluorescence workflow in which label density, position, and photostability are optimized rather than treated as fixed properties.

• SB 202190: Practical p38 MAP Kinase Workflows

  2026-09-04

  SB 202190 (FHPI) is a cell-permeable p38 MAP kinase inhibitor for separating inflammatory signaling, stress responses, and cell-death phenotypes in cultured cells. This practical guide connects its ATP-competitive activity with apoptosis assay design, RIPK1 pathway questions, cancer therapeutics research, and neuroinflammation workflows.

• ER-Targeted Peptide Self-Assembly in Cancer Cells

  2026-09-04

  The reference study develops an alkaline-phosphatase-instructed peptide that self-assembles at the endoplasmic reticulum after incorporating a p-toluenesulfonamide targeting group. This design selectively increases ER stress and cancer-cell death through apoptosis and necroptosis while reducing the concentration limitation associated with intracellular peptide self-assembly.

• Bortezomib (PS-341) in Proteasome Research

  2026-09-04

  Bortezomib (PS-341) turns proteasome inhibition into a practical tool for connecting protein turnover with apoptosis, invasion, and treatment response. This workflow-focused guide shows how to use it alongside viability, apoptosis, and pathway assays to interrogate the MAPK10–KRT16 axis in cancer models.

• VX-765 Workflows for Caspase-1 Research

  2026-09-03

  VX-765 enables selective interrogation of caspase-1-driven cytokine maturation and pyroptotic death across biochemical, cellular, and disease-model workflows. This guide combines practical assay design with time-resolved death analysis inspired by modern functional-genomic screening.

• TPCA-1: An IKK-2 Inhibitor for Inflammation Studies

  2026-09-02

  TPCA-1 is a selective IKK-2 inhibitor for connecting NF-κB activity with cytokine output, inflammatory phenotypes, and regulated cell-death assays. Its strong kinase selectivity and defined monocyte and arthritis-model performance make it useful for mechanism-first inflammation research when paired with orthogonal viability and phosphorylation readouts.

• LDH Cytotoxicity Assay Kit: Practical Guide

  2026-09-02

  The LDH Cytotoxicity Assay Kit (K2228) provides a non-radioactive approach to cell cytotoxicity measurement by quantifying LDH released into culture medium after membrane damage. It is useful for comparative cell damage studies, but it should not be used alone to identify apoptosis mechanisms, establish absolute cell counts, or support automated high-throughput claims without laboratory validation.

• KU-60019: ATM Kinase Inhibitor Workflow

  2026-09-01

  KU-60019 enables selective ATM kinase inhibition for dissecting DNA damage response, radiation sensitivity, and glioma invasion phenotypes. This workflow combines pathway-level validation with functional assays while separating established product evidence from exploratory cross-domain hypotheses.

• Atropo-Enantioselective Suzuki Synthesis

  2026-09-01

  Herrbach and co-workers developed a catalytic atropo-enantioselective Suzuki coupling to construct the axially chiral biaryl core of an antimitotic rhazinilam analogue. Ligand screening identified a binaphthyl phosphine that provided up to 40% enantiomeric excess, establishing an important proof of concept while also exposing the limitations of asymmetric control in this biologically relevant scaffold.

• Dual-Action Inhibitors and p38α Dephosphorylation

  2026-08-31

  A 2024 bioRxiv preprint shows that selected kinase inhibitors can do more than occupy the p38α active site: they can also expose the activation-loop phosphothreonine to the phosphatase WIP1. The structural and biochemical findings introduce conformational control of dephosphorylation as a potential route to more durable and selective kinase pathway inhibition.

• TPPU: A Practical sEH Assay Decision Framework

  2026-08-31

  TPPU is a potent soluble epoxide hydrolase inhibitor for dissecting fatty acid epoxide signaling in inflammatory pain and bone biology. This article presents a compartment-aware assay strategy that connects target engagement, lipid mediator measurements, Nrf2-linked phenotypes, and translational limitations.

• SPOP Molecular Glue Degradation in Melanoma Immunotherapy

  2026-08-30

  The reference study identifies SPOP as a melanoma-promoting E3 ligase that degrades the innate immune sensor STING, thereby limiting interferon signaling. It further shows that SPOP inhibitors can act as molecular glues, redirecting SPOP toward CBX4 and enhancing STING-dependent responses that improve checkpoint blockade and CAR-T treatment in preclinical models.

• YM 58483 (BTP2): SOCE Blocker for Ca2+ Research

  2026-08-29

  YM 58483, also called BTP2, is a store-operated Ca2+ entry inhibitor that suppresses sustained calcium influx through CRAC and TRP channels. Product data report approximately 17 nM inhibition of PHA-induced IL-2 production, while a 2025 salivary-gland study used YM58483 to investigate ORAI2-dependent postirradiation fibrosis.

8622 records 2/575 page Previous Next 12345 下5页 Last page